<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk stratification after acute ST-elevation myocardial infarction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk stratification after acute ST-elevation myocardial infarction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Risk stratification after acute ST-elevation myocardial infarction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph S Alpert, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Simons, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter WF Wilson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey A Breall, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pamela S Douglas, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan S Jaffe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Pellikka, MD, FACC, FAHA, FASE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In patients with ST-elevation myocardial infarction (STEMI), the likelihood of adverse events can be estimated from clinical assessment, risk factors, and risk models.</p><p>The general approach to risk stratification for patients with STEMI will be reviewed here.</p><p>Risk stratification for patients with acute non-ST elevation acute coronary syndromes and for those at risk for life-threatening arrhythmias is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/76.html" rel="external">"Risk stratification after non-ST elevation acute coronary syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EARLY RISK STRATIFICATION</span><span class="headingEndMark"> — </span>In general, risk stratification does not influence the acute management of patients with STEMI. Patients with STEMI can undergo risk assessment with either the TIMI risk score (<a class="calc calc_professional" href="/z/d/html/13467.html" rel="external">calculator 1</a>) or the GRACE risk model  (<a class="graphic graphic_table graphicRef112215" href="/z/d/graphic/112215.html" rel="external">table 1</a>). These tools include predictors of poor outcomes identified in large databases of patients with STEMI. (See  <a class="medical medical_review" href="/z/d/html/88759.html" rel="external">"Risk factors for adverse outcomes after ST-elevation myocardial infarction"</a>.)</p><p>A report published in 1998 from the National Registry of Myocardial Infarction (NRMI) evaluated data on 170,143 patients admitted with an acute MI (with or without ST-segment elevation) in an attempt to identify patients at high risk [<a href="#rid1">1</a>]. Significant risk factors included age over 70 years, prior MI, Killip class at admission  (<a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">table 2</a>), anterior MI, and the combination of hypotension and tachycardia.</p><p>Similar data were reported by the GUSTO trial of 41,021 patients, which found that predictors of one-year mortality among those who survived to 30 days after their MI included [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Demographics, including older age (&gt;55), lower weight (≤80 kg), previous MI, and previous bypass surgery. In another population-based study of 2541 patients, severe obesity (BMI &gt;30 kg/m<sup>2</sup>) also increased the risk of a cardiac event [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences", section on 'Heart disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Larger MIs, as determined by higher Killip class, anterior wall MI, lower blood pressure, faster heart rate (&gt;115 bpm), longer QRS duration (&gt;125 ms), lower left ventricular ejection fraction (LVEF), heart failure (HF) and pulmonary edema, and cardiogenic shock.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of cardiac risk factors, including smoking, hypertension, and prior cerebrovascular disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other findings such as in-hospital stroke, ventricular or supraventricular arrhythmias, absence of revascularization, and being a Black person.</p><p></p><p>Based upon these findings and analyses from other large clinical trials and registries, a number of different risk scores have been developed to assess short- and long-term outcomes after STEMI [<a href="#rid4">4-10</a>]. Only two specifically addressed patients treated with primary percutaneous coronary intervention, which is the current modality of choice [<a href="#rid5">5,7</a>].</p><p class="headingAnchor" id="H3"><span class="h2">TIMI risk score</span><span class="headingEndMark"> — </span>The TIMI risk score, based upon data from 15,000 patients with an STEMI eligible for fibrinolytic therapy, is an arithmetic sum of eight independent predictors of mortality [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥75 years – 3 points</p><p class="bulletIndent1"><span class="glyph">●</span>Age 65 to 74 years – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>History of diabetes, hypertension, or angina – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Systolic blood pressure &lt;100 mmHg – 3 points</p><p class="bulletIndent1"><span class="glyph">●</span>Heart rate &gt;100/min – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Killip class II to IV  (<a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">table 2</a>) and – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Weight &lt;67 kg – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Anterior ST elevation or left bundle branch block – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Time to reperfusion therapy &gt;4 hours – 1 point</p><p></p><p>There is a continuous relationship between mortality and score; a score of 0 to &gt;8 was associated with a 30-day mortality of 0.8 to 36 percent, while the one-year mortality among those surviving the first 30 days ranges from 1 to 17 percent (<a class="calc calc_professional" href="/z/d/html/13467.html" rel="external">calculator 1</a>).</p><p>The accuracy of the TIMI risk score to predict in-hospital mortality was validated in a community-based population of 84,029 patients; the predictive accuracy of the TIMI risk score was the same in those treated with fibrinolysis or percutaneous coronary intervention, but underestimated mortality in those not undergoing reperfusion therapy (<a class="calc calc_professional" href="/z/d/html/13467.html" rel="external">calculator 1</a>) [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H4"><span class="h2">TIMI risk index</span><span class="headingEndMark"> — </span>The TIMI risk index (TRI) is a simpler model derived from the InTIME-II trial of fibrinolytic therapy [<a href="#rid8">8</a>] and then validated in other populations to predict in-hospital mortality [<a href="#rid12">12,13</a>]. It can be used simultaneously with the TIMI risk score</p><p>The TRI is calculated from the following equation, using data obtained at presentation  (<a class="graphic graphic_table graphicRef52542" href="/z/d/graphic/52542.html" rel="external">table 3</a>) [<a href="#rid8">8</a>]:</p><div class="formulaContainer"><div class="formula"><p>  TRI  =  (Heart rate  x  [age/10] squared)  /  systolic pressure</p></div></div><p>The TRI was applied to over 153,000 patients with STEMI in the National Registry of Myocardial Infarction (NRMI) in the United States [<a href="#rid12">12</a>]. There was a graded relationship to in-hospital mortality, ranging from 0.6 to 60 percent from the lowest (0 to &lt;10) to the highest scores (≥80) in patients who received reperfusion therapy and from 1.9 to 52.2 percent in patients who did not receive reperfusion therapy [<a href="#rid12">12</a>]. Patients with a TRI &lt;30 were at low risk. The percent of patients at high risk (TRI &gt;60) was 14.1 percent in those who were not reperfused compared to 2.1 percent in those who were reperfused [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H5"><span class="h2">GRACE risk model</span><span class="headingEndMark"> — </span>The TIMI risk score was derived from clinical trial databases, although it has been validated in community-based populations [<a href="#rid11">11,12</a>]. The GRACE registry, a global registry of acute coronary syndrome (ACS) patients from 94 hospitals in 14 countries, developed two models to estimate the risk of both in-hospital and six-month mortality among all patients with an ACS.</p><p>The in-hospital model was based upon data from 11,389 patients with either an STEMI or a non-ST elevation ACS [<a href="#rid5">5</a>]. This model was then validated based upon data from an additional 3972 patients from GRACE and 12,142 patients from the GUSTO IIb trial. Eight independent risk factors were found to account for almost 90 percent of the prognostic information:</p><p class="bulletIndent1"><span class="glyph">●</span>Age</p><p class="bulletIndent1"><span class="glyph">●</span>Killip class  (<a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Systolic blood pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of ST-segment deviation</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac arrest during presentation</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine concentration</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of elevated serum cardiac biomarkers</p><p class="bulletIndent1"><span class="glyph">●</span>Heart rate</p><p></p><p>Point scores were assigned for each predictive factor and are added together to arrive at an estimate of the risk of in-hospital mortality. A nomogram was published with the GRACE risk model to allow calculation of the risk score [<a href="#rid5">5,15</a>].</p><p>The six-month model was based upon data from 15,007 patients and validated in a cohort of 7638 patients, all in the GRACE registry [<a href="#rid15">15</a>]. The variables incorporated into this model include age, prior history of HF, prior history of MI, resting heart rate, systolic blood pressure, ST-segment depression, initial serum creatinine concentration, elevated serum cardiac biomarkers, and performance of in-hospital percutaneous coronary intervention (PCI). The six-month mortality risk based upon this model can be calculated using a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.outcomes-umassmed.org%2Frisk_models_grace_orig.aspx&amp;token=h3p1k3ENLOEECtvLd0Z2MXgvjcmdL7dGgwnk9nla5KdbkxG67U971XDxjTslVriAydOg%2B9gWAUEAkqtgMUZfJ5tYquazY5QqYPGPo677nvE%3D&amp;TOPIC_ID=78" target="_blank">website</a>.</p><p class="headingAnchor" id="H183452799"><span class="h2">CHADS2 score</span><span class="headingEndMark"> — </span>While the GRACE prediction model is well validated and its use is recommended by multiple guideline organizations, its complexity makes it somewhat difficult to use in some clinical settings. The value of the CHADS2-VASc score, which is a well validated tool for predicting the risk of stroke in patients with atrial fibrillation, was evaluated in a study of more than 2300 patients with ACS (37 percent with STEMI; 19 percent with atrial fibrillation [AF]) cared for between 1995 and 2001 [<a href="#rid16">16</a>]. All-cause mortality at 10 years was strongly associated with the CHADS2 score in patients with and without AF. As expected, the more complex GRACE score provided a better prediction for short- and long-term mortality. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'Use'</a>.)</p><p class="headingAnchor" id="H1446889610"><span class="h2">ACTION registry score</span><span class="headingEndMark"> — </span>The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry was used to develop a risk score to predict in-hospital mortality following STEMI and NSTEMI [<a href="#rid17">17</a>]. Multivariable analyses of data from 243,440 patients showed that greater heart rate, lower systolic blood pressure, life-threatening presentations (cardiac arrest, cardiogenic shock, or HF), STEMI at presentation, lower creatinine clearance, and higher troponin values were associated with death during the hospitalization. The C statistic was very good at 0.88.</p><p>The ACTION score is likely to be most helpful for persons with moderate to severe disease and reflects more contemporary experience than TIMI or GRACE.</p><p>Two additional multivariable models have been devised and validated for patients exclusively undergoing primary PCI: the Zwolle primary PCI risk index and the CADILLAC risk score.</p><p class="headingAnchor" id="H7"><span class="h2">Zwolle primary PCI index</span><span class="headingEndMark"> — </span>A risk index based upon a primary PCI population was developed in Zwolle, the Netherlands from data on 1791 patients undergoing primary PCI between 1994 and 2001 [<a href="#rid6">6</a>]. Significant independent risk factors for 30-day mortality were incorporated into the Zwolle index, including Killip class  (<a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">table 2</a>) and post-PCI TIMI flow grade  (<a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">table 4</a>), age, number of diseased vessels, location of infarction, and time to reperfusion. The risk index was validated in an additional group of 747 patients with similar characteristics treated with primary PCI between 2001 and 2003.</p><p>Based upon the Zwolle risk index, more than two-thirds of patients undergoing primary PCI were classified as low risk (risk score ≤3) [<a href="#rid6">6</a>]. For these patients, the mortality rate was 0.1 percent at two days and 0.2 percent between 2 and 10 days post-MI. It was suggested that such low-risk patients could safely be discharged early (48 hours after PCI).</p><p class="headingAnchor" id="H8"><span class="h2">CADILLAC PCI risk score</span><span class="headingEndMark"> — </span>A second primary PCI risk model was derived from the 2082 patients in the CADILLAC trial of abciximab or placebo and stenting or angioplasty in primary PCI and then validated using data from the 900 patients in the Stent-PAMI trial [<a href="#rid7">7</a>]. Seven variables, which are readily available at the time of intervention, were weighted according to their odds ratio for one-year mortality  (<a class="graphic graphic_table graphicRef70537" href="/z/d/graphic/70537.html" rel="external">table 5</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>LVEF &lt;40 percent – 4 points</p><p class="bulletIndent1"><span class="glyph">●</span>Killip class 2/3 – 3 points </p><p class="bulletIndent1"><span class="glyph">●</span>Renal insufficiency (estimated creatinine clearance &lt;60 mL/min) – 3 points</p><p class="bulletIndent1"><span class="glyph">●</span>TIMI flow grade after PCI 0 to 2 – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;65 years – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia (hematocrit &lt;39 percent in men and &lt;36 percent in women) – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Triple-vessel disease – 2 points</p><p></p><p>In both the derivation and validation models, patients could be stratified into three risk groups that predicted 30-day and one-year mortality:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk (score 0 to 2) – 0.1 to 0.2 percent at 30 days and 0.8 to 0.9 percent at one year</p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate risk (score 3 to 5) – 1.3 to 1.9 percent at 30 days and 4.0 to 4.5 percent at one year</p><p class="bulletIndent1"><span class="glyph">●</span>High risk (score ≥6) – 6.6 to 8.1 percent at 30 days and 12.4 to 13.2 percent at one year</p><p></p><p>The percentage of patients in these three groups was 56, 24, and 20 percent, respectively. The results compared favorably with the TIMI risk score, which was based upon patients undergoing fibrinolysis, and Zwolle primary PCI index.</p><p class="headingAnchor" id="H9"><span class="h2">Comparison of risk scores</span><span class="headingEndMark"> — </span>The prognostic value of the TIMI, PAMI, CADILLAC PCI, and GRACE risk scores was directly compared in 855 registry patients with STEMI, but without cardiogenic shock, who underwent primary PCI [<a href="#rid18">18</a>]. The TIMI, PAMI, and CADILLAC scores had relatively high and similar predictive accuracies for 30-day and one-year mortality; the GRACE model performed less well. The CADILLAC PCI score was judged to be unhelpful prior to angiography because LVEF is a key component.</p><p class="headingAnchor" id="H3238719706"><span class="h2">Machine learning models</span><span class="headingEndMark"> — </span>Machine learning models that predict in-hospital mortality after acute MI have been created, but are not more accurate than the models listed above [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H32"><span class="h1">LATE RISK STRATIFICATION</span><span class="headingEndMark"> — </span>The major components of late risk stratification are clinical status and LVEF. Methods used to determine the risk of arrhythmic death are discussed separately. These include ventricular arrhythmias and late potentials on signal-averaged electrocardiogram (ECG). (See  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a>.)</p><p class="headingAnchor" id="H33"><span class="h2">Left ventricular ejection fraction</span><span class="headingEndMark"> — </span>Assessment of resting LV function is an important part of risk stratification in patients with acute MI and was recommended by the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) and 2012 European Society of Cardiology STEMI guidelines [<a href="#rid20">20-22</a>]. Echocardiography is preferred to magnetic resonance imaging in the European guideline, while the United States guideline makes no preference for the type of imaging modality. Patients with LV systolic dysfunction, defined as LVEF &lt;50 percent, have increased mortality at six months and one year  (<a class="graphic graphic_figure graphicRef75743" href="/z/d/graphic/75743.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef68071" href="/z/d/graphic/68071.html" rel="external">figure 2</a>) [<a href="#rid23">23-25</a>]. The increase in mortality is most pronounced in the minority of patients with an LVEF ≤30 percent. In addition, patients with LVEF ≤35 percent are at increased risk for sudden cardiac death after MI and should be considered candidates for an implantable cardioverter-defibrillator. Moreover, the degree of LVEF between two and seven days following an acute MI and second determination 2 to 12 weeks following an MI predicted a high risk of sudden death and mortality. Patients with no recovery of LVEF between these two time intervals are at a particularly high risk for these complications [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p>LVEF is usually measured before discharge in the absence of a specific indication (eg, HF or suspected mechanical complication) for which echocardiography may be indicated early in the hospitalization. However, measurements during hospitalization may be misleading, since improvement in LVEF, beginning within three days and largely complete by 30 days, is common in patients who are reperfused [<a href="#rid27">27</a>]. Two separate studies have shown that approximately 58 percent of patients significantly improve their LVEF after reperfusion in acute STEMI [<a href="#rid28">28,29</a>]. This may reflect, at least in part, recovery from myocardial stunning [<a href="#rid28">28,30</a>] since it is associated with a reduction in the size of the myocardial perfusion defect [<a href="#rid29">29</a>]. Patients with improved LVEF may have significantly lower mortality than those who show no improvement (1.2 versus 5.6 percent at three years in one study) [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/1527.html" rel="external">"Clinical syndromes of stunned or hibernating myocardium", section on 'Acute myocardial infarction'</a>.)</p><p>Among patients with an STEMI who have an interpretable ECG (ie, no left bundle branch block, paced rhythm, or LV hypertrophy with strain pattern), the absence of an anterior infarction, a previous Q wave MI, or a history of HF predicts an LVEF of at least 40 percent (positive predictive value of 91 to 98 percent) [<a href="#rid31">31,32</a>]. The LVEF is variable among patients who do not fit the prediction rule.</p><p class="headingAnchor" id="H34"><span class="h2">Right ventricular ejection fraction</span><span class="headingEndMark"> — </span>Long-term impairment of right ventricular systolic function after MI is associated with a worse prognosis (see  <a class="medical medical_review" href="/z/d/html/75.html" rel="external">"Right ventricular myocardial infarction", section on 'Long-term prognosis'</a>). One study noted that patients with STEMI who had right ventricular remodeling (dilation) had a significantly lower survival rate [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2981945836"><span class="h2">Mitral regurgitation</span><span class="headingEndMark"> — </span>In addition to the poor prognosis associated with acute mitral regurgitation (MR) caused by papillary muscle dysfunction or rupture, chronic MR is also associated with a worse prognosis:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, moderate to severe ischemic MR was present in 9.3 percent of patients, and one-year mortality was higher in those with MR compared with those who did not have MR after MI (15 versus 7.3 percent; adjusted HR 1.4, 95% CI 1.1-2.2) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of patients who had an MI, moderate to severe MR was present in 25 percent of patients, and survival at one year was lower in patients with moderate to severe MR compared with those without MR (approximate one-year survival (80 versus 95 percent) [<a href="#rid35">35</a>].</p><p></p><p>Additional information on acute and chronic MR can be found separately. (See  <a class="medical medical_review" href="/z/d/html/8170.html" rel="external">"Acute mitral regurgitation in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation", section on 'Identifying the cause of MR'</a>.)</p><p class="headingAnchor" id="H35"><span class="h2">Stress testing</span><span class="headingEndMark"> — </span>The role of noninvasive stress testing after STEMI is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Stress testing'</a>.)</p><p class="headingAnchor" id="H1975721940"><span class="h2">Other post-myocardial infarction risk factors</span><span class="headingEndMark"> — </span>A variety of other characteristics have been shown to correlate with late prognosis following acute MI. For example, the extent of angiographic coronary artery disease was a predictor for the development of HF [<a href="#rid36">36</a>]. Environmental factors such as living in an area with a lower mean income or being socially disadvantaged increased the risk for post-MI hospitalization and mortality [<a href="#rid37">37-39</a>]. Two biomarkers, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and growth differentiation factor-15, were strongly associated with all-cause death in patients with an acute coronary syndrome, most of whom had an acute MI [<a href="#rid40">40</a>]. Worsening postdischarge renal function in patients with type 2 diabetes mellitus and a recent ACS were strong predictors of adverse cardiovascular events, including all-cause mortality [<a href="#rid41">41</a>]. Additionally, patients who had influenza and other viral respiratory infections concomitant with acute MI had worse outcomes than patients without viral syndromes [<a href="#rid42">42</a>]. Another research group developed a 30-day and one-year risk model for predicting mortality in ACS. They used a variety of biomarkers including troponin, creatinine clearance, NT-proBNP, C-reactive protein, and age in their model, which had a high predictive value [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H2096510295"><span class="h2">Young adults with myocardial infarction</span><span class="headingEndMark"> — </span>Over a median follow-up of more than 11 years, very young patients (&lt;40 years of age) with MI had a similar risk of all-cause and cardiovascular mortality when compared with patients ages 41 to 50 [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H3262550533"><span class="h2">Sex differences in cardiac death after myocardial infarction</span><span class="headingEndMark"> — </span>Females with STEMI have been noted to have worse outcomes compared with males when adjusted for the anatomic complexity of CAD. This is particularly true for females who undergo interventional therapy for STEMI [<a href="#rid45">45,46</a>].</p><p class="headingAnchor" id="H3812426442"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H328427464"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of stratification</strong> – In patients with ST-elevation myocardial infarction (STEMI), the likelihood of adverse events can be estimated from clinical assessment, risk factors, and risk models.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early risk stratification</strong> – In general, risk stratification does not influence the acute management of patients with STEMI. Patients with STEMI can undergo risk assessment with either the TIMI risk score (<a class="calc calc_professional" href="/z/d/html/13467.html" rel="external">calculator 1</a>) or the GRACE risk model  (<a class="graphic graphic_table graphicRef112215" href="/z/d/graphic/112215.html" rel="external">table 1</a>). (See <a class="local">'TIMI risk score'</a> above and <a class="local">'GRACE risk model'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Late risk stratification</strong> – The major components of late risk stratification are clinical status and left ventricular ejection fraction (LVEF). (See <a class="local">'Left ventricular ejection fraction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of sudden death</strong> – Methods used to determine the risk of arrhythmic death are discussed separately. These include ventricular arrhythmias and late potentials on signal-averaged ECG. (See  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J 1998; 135:786.</a></li><li><a class="nounderline abstract_t">Califf RM, Pieper KS, Lee KL, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000; 101:2231.</a></li><li><a class="nounderline abstract_t">Rea TD, Heckbert SR, Kaplan RC, et al. Body mass index and the risk of recurrent coronary events following acute myocardial infarction. Am J Cardiol 2001; 88:467.</a></li><li><a class="nounderline abstract_t">Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102:2031.</a></li><li><a class="nounderline abstract_t">Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163:2345.</a></li><li><a class="nounderline abstract_t">De Luca G, Suryapranata H, van 't Hof AW, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation 2004; 109:2737.</a></li><li><a class="nounderline abstract_t">Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45:1397.</a></li><li><a class="nounderline abstract_t">Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358:1571.</a></li><li><a class="nounderline abstract_t">Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001; 22:2085.</a></li><li><a class="nounderline abstract_t">Tu JV, Austin PC, Walld R, et al. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol 2001; 37:992.</a></li><li><a class="nounderline abstract_t">Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001; 286:1356.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Morrow DA, Frederick PD, et al. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:783.</a></li><li><a class="nounderline abstract_t">Rathore SS, Weinfurt KP, Gross CP, Krumholz HM. Validity of a simple ST-elevation acute myocardial infarction risk index: are randomized trial prognostic estimates generalizable to elderly patients? Circulation 2003; 107:811.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Morrow DA, Frederick PD, et al. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol 2006; 47:1553.</a></li><li><a class="nounderline abstract_t">Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291:2727.</a></li><li><a class="nounderline abstract_t">Poçi D, Hartford M, Karlsson T, et al. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest 2012; 141:1431.</a></li><li><a class="nounderline abstract_t">McNamara RL, Kennedy KF, Cohen DJ, et al. Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction. J Am Coll Cardiol 2016; 68:626.</a></li><li><a class="nounderline abstract_t">Lev EI, Kornowski R, Vaknin-Assa H, et al. Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2008; 102:6.</a></li><li><a class="nounderline abstract_t">Khera R, Haimovich J, Hurley NC, et al. Use of Machine Learning Models to Predict Death After Acute Myocardial Infarction. JAMA Cardiol 2021; 6:633.</a></li><li><a class="nounderline abstract_t">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.</a></li><li><a class="nounderline abstract_t">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.</a></li><li><a class="nounderline abstract_t">Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.</a></li><li><a class="nounderline abstract_t">Nicolosi GL, Latini R, Marino P, et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Eur Heart J 1996; 17:1646.</a></li><li><a class="nounderline abstract_t">Burns RJ, Gibbons RJ, Yi Q, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002; 39:30.</a></li><li><a class="nounderline abstract_t">Zaret BL, Wackers FJ, Terrin ML, et al. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. J Am Coll Cardiol 1995; 26:73.</a></li><li><a class="nounderline abstract_t">Chew DS, Heikki H, Schmidt G, et al. Change in Left Ventricular Ejection Fraction Following First Myocardial Infarction and Outcome. JACC Clin Electrophysiol 2018; 4:672.</a></li><li><a class="nounderline abstract_t">Daubert MA, White JA, Al-Khalidi HR, et al. Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. Am Heart J 2020; 223:87.</a></li><li><a class="nounderline abstract_t">Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001; 134:451.</a></li><li><a class="nounderline abstract_t">Ndrepepa G, Mehilli J, Martinoff S, et al. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol 2007; 50:149.</a></li><li><a class="nounderline abstract_t">Sheehan FH, Doerr R, Schmidt WG, et al. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol 1988; 12:289.</a></li><li><a class="nounderline abstract_t">Silver MT, Rose GA, Paul SD, et al. A clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Ann Intern Med 1994; 121:750.</a></li><li><a class="nounderline abstract_t">Tobin K, Stomel R, Harber D, et al. Validation in a community hospital setting of a clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Arch Intern Med 1999; 159:353.</a></li><li><a class="nounderline abstract_t">Chimed S, van der Bijl P, Lustosa RP, et al. Prognostic Relevance of Right Ventricular Remodeling after ST-Segment Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention. Am J Cardiol 2022; 170:1.</a></li><li><a class="nounderline abstract_t">Perl L, Bental T, Orvin K, et al. Trends in Ischemic Mitral Regurgitation Following ST-Elevation Myocardial Infarction Over a 20-Year Period. Front Cardiovasc Med 2021; 8:796041.</a></li><li><a class="nounderline abstract_t">Sharma H, Radhakrishnan A, Nightingale P, et al. Mitral Regurgitation Following Acute Myocardial Infarction Treated by Percutaneous Coronary Intervention-Prevalence, Risk factors, and Predictors of Outcome. Am J Cardiol 2021; 157:22.</a></li><li><a class="nounderline abstract_t">Gerber Y, Weston SA, Enriquez-Sarano M, et al. Atherosclerotic Burden and Heart Failure After Myocardial Infarction. JAMA Cardiol 2016; 1:156.</a></li><li><a class="nounderline abstract_t">Spatz ES, Beckman AL, Wang Y, et al. Geographic Variation in Trends and Disparities in Acute Myocardial Infarction Hospitalization and Mortality by Income Levels, 1999-2013. JAMA Cardiol 2016; 1:255.</a></li><li><a class="nounderline abstract_t">Berman AN, Biery DW, Ginder C, et al. Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry. JAMA Cardiol 2021; 6:880.</a></li><li><a class="nounderline abstract_t">Loccoh EC, Joynt Maddox KE, Wang Y, et al. Rural-Urban Disparities in Outcomes of Myocardial Infarction, Heart Failure, and Stroke in the United States. J Am Coll Cardiol 2022; 79:267.</a></li><li><a class="nounderline abstract_t">Lindholm D, James SK, Gabrysch K, et al. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. JAMA Cardiol 2018; 3:1160.</a></li><li><a class="nounderline abstract_t">Morici N, Savonitto S, Ponticelli C, et al. Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. Am J Med 2017; 130:1068.</a></li><li><a class="nounderline abstract_t">Vejpongsa P, Kitkungvan D, Madjid M, et al. Outcomes of Acute Myocardial Infarction in Patients with Influenza and Other Viral Respiratory Infections. Am J Med 2019; 132:1173.</a></li><li><a class="nounderline abstract_t">Westerhout CM, Fu Y, Lauer MS, et al. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. J Am Coll Cardiol 2006; 48:939.</a></li><li><a class="nounderline abstract_t">Yang J, Biery DW, Singh A, et al. Risk Factors and Outcomes of Very Young Adults Who Experience Myocardial Infarction: The Partners YOUNG-MI Registry. Am J Med 2020; 133:605.</a></li><li><a class="nounderline abstract_t">Burgess SN, Juergens CP, Nguyen TL, et al. Comparison of Late Cardiac Death and Myocardial Infarction Rates in Women Vs Men With ST-Elevation Myocardial Infarction. Am J Cardiol 2020; 128:120.</a></li><li><a class="nounderline abstract_t">Asleh R, Manemann SM, Weston SA, et al. Sex Differences in Outcomes After Myocardial Infarction in the Community. Am J Med 2021; 134:114.</a></li></ol></div><div id="topicVersionRevision">Topic 78 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588407" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811588" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524051" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Body mass index and the risk of recurrent coronary events following acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044416" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581255" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Predictors of hospital mortality in the global registry of acute coronary events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159293" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15862409" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11716882" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11686666" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263626" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Development and validation of the Ontario acute myocardial infarction mortality prediction rules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560541" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15312859" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591749" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Validity of a simple ST-elevation acute myocardial infarction risk index: are randomized trial prognostic estimates generalizable to elderly patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630990" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187054" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22016485" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27491907" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18572028" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33688915" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Use of Machine Learning Models to Predict Death After Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247303" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247304" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22922416" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922912" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11755283" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797778" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29798797" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Change in Left Ventricular Ejection Fraction Following First Myocardial Infarction and Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203684" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255520" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17616299" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3392324" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944052" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10030308" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Validation in a community hospital setting of a clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35210068" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prognostic Relevance of Right Ventricular Remodeling after ST-Segment Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35097016" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Trends in Ischemic Mitral Regurgitation Following ST-Elevation Myocardial Infarction Over a 20-Year Period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34417016" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mitral Regurgitation Following Acute Myocardial Infarction Treated by Percutaneous Coronary Intervention-Prevalence, Risk factors, and Predictors of Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27437886" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Atherosclerotic Burden and Heart Failure After Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27438103" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Geographic Variation in Trends and Disparities in Acute Myocardial Infarction Hospitalization and Mortality by Income Levels, 1999-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34009238" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35057913" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rural-Urban Disparities in Outcomes of Myocardial Infarction, Heart Failure, and Stroke in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30427997" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28344139" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145880" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcomes of Acute Myocardial Infarction in Patients with Influenza and Other Viral Respiratory Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949483" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31715169" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk Factors and Outcomes of Very Young Adults Who Experience Myocardial Infarction: The Partners YOUNG-MI Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32650905" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of Late Cardiac Death and Myocardial Infarction Rates in Women Vs Men With ST-Elevation Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32622868" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sex Differences in Outcomes After Myocardial Infarction in the Community.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
